Topline results from TREK-AD: a randomized, double-blind, placebo-controlled, Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis

Eric Simpson, Melinda Gooderham, Leon H Kircik, Todd Schlesinger, James Del Rosso, Dédée Murrell, Steven Thng, Jacek Szepietowski, Karen A Veverka, Alexandre Kaoukhov, April W. Armstrong

32nd European Academy of Dermatology and Venereology Congress (EADV), October 2023

For further details on the presentation, please refer to our press release.